LianBio

Equities

LIANY

US53000N1081

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:14:03 2024-05-03 pm EDT			5-day change	1st Jan Change
0.305 ^USD	-2.89%		+8.62%	-93.18%

Mar. 18	LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index	CI
Mar. 15	ADRs End Lower; Akso Health Group Declines 23%	DJ

LianBio to Communicate an Update on the Ongoing Strategic Review in the First Quarter of 2024

December 18, 2023

LianBio (NasdaqGM:LIAN)'s Board of Directors will continue to represent the best interests of LianBio and its shareholders and evaluate strategic alternatives for the Company. The Board of Directors expects to communicate an update on the ongoing strategic review in the first quarter of 2024.

Latest news about LianBio

LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index	Mar. 17	CI
ADRs End Lower; Akso Health Group Declines 23%	Mar. 15	DJ
LianBio to Start Winding Down Operations; Complete Dissolution Expected in 2027	Feb. 13	MT
LianBio Announces Completion of Strategic Review	Feb. 13	CI
Nanobiotix: transfer of NBTXR3 rights in Asia	Dec. 27	CF
Nanobiotix Partner Transfers Asian Commercialization Rights for Oncology Therapy to Johnson & Johnson Unit	Dec. 27	MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday	Dec. 26	MT
LianBio Assigns Rights to Nanobiotix's Oncology Therapy in China, Other Asian Markets to Janssen Pharmaceutica	Dec. 26	MT
LianBio Enters into Agreement with Janssen Pharmaceutica to Assign its Rights for NBTXR3 in China and Other Asian Markets	Dec. 26	CI
Jefferies Downgrades LianBio to Hold From Buy, Adjusts Price Target to $4 From $7	Dec. 22	MT
LianBio Finance Chief Resigns, Names Interim CFO	Dec. 20	MT
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	Dec. 20	MT
LianBio Announces Chief Financial Officer Changes	Dec. 20	CI
LianBio CEO Yizhe Wang Resigns; Board Member Adam Stone Named in Interim	Dec. 19	MT
Lianbio Announces Resignation of Yizhe Wang as Member of the Board of Directors	Dec. 19	CI
Lianbio Announces Chief Executive Officer Changes	Dec. 19	CI
LianBio to Communicate an Update on the Ongoing Strategic Review in the First Quarter of 2024	Dec. 18	CI
LianBio Rejects Concentra Biosciences' Unsolicited Acquisition Proposal	Dec. 07	MT
Concentra Biosciences, LLC cancelled the acquisition of LianBio from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others.	Dec. 05	CI
LianBio Receives Unsolicited Proposal From Concentra Biosciences to be Acquired for $4.30 Per Share Plus Contingent Value Right	Dec. 01	MT
Concentra Biosciences, LLC submit non-binding proposal to acquire LianBio.	Nov. 29	CI
BofA Securities Adjusts LianBio Price Target to $5 From $6, Maintains Buy Rating	Nov. 20	MT
LianBio Q3 Loss Widens	Nov. 13	MT
LianBio Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis	23-10-30	CI

Chart LianBio

Duration

Period

More charts

Company Profile

LianBio is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. It has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
LIANBIO	-93.18%	33.21M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B

Bio Therapeutic Drugs

LianBio

Equities

LIANY

US53000N1081

Biotechnology & Medical Research

LianBio to Communicate an Update on the Ongoing Strategic Review in the First Quarter of 2024

Latest news about LianBio

Chart LianBio

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs